Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
Abstract Background Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURION). Methods Patients were randomized 1:1:...
Guardado en:
Autores principales: | C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett, T Schwedt |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/55ad02cbed234cf4a58c92860dd14765 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
por: Lo Castro F, et al.
Publicado: (2021) -
Exploring the Hereditary Nature of Migraine
por: Bron C, et al.
Publicado: (2021) -
Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks
por: Yigit M, et al.
Publicado: (2018) -
The role of diet in the prevention of migraine attacks
por: O. O. Kopchak, et al.
Publicado: (2021) -
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Timothy R. Smith, et al.
Publicado: (2021)